Clinical Trials Logo

Thrombocytopathy clinical trials

View clinical trials related to Thrombocytopathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05985668 Recruiting - Platelet Disorder Clinical Trials

Towards Improved Diagnostics for Suspected Platelet Function Disorders

Start date: September 5, 2023
Phase:
Study type: Observational

This study aims to improve platelet function testing during bleeding investigations. To this end, the study will evaluate the diagnostic accuracy of novel platelet function tests in patients with confirmed or suspected platelet function disorders. Study participants will be recruited from patients that are referred to or treated at the Coagulation Unit, Karolinska University Hospital, and Pediatric Coagulation Unit, Astrid Lingren Children's Hospital.

NCT ID: NCT05654766 Not yet recruiting - Acute Leukemia Clinical Trials

Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies

Start date: January 2, 2023
Phase:
Study type: Observational

The purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets for use in the differential diagnosis of thrombocytopenia and platelet defects.

NCT ID: NCT02461329 Not yet recruiting - Clinical trials for Hemorrhage, Surgical

Comparison of the Effects of Gelatine Versus Balanced Crystalloid Solution for Volume Therapy

Gelaring
Start date: May 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether volume therapy with a solution of gelatine has negative impact on coagulation, platelet function, renal function in comparison with crystaloid solution (Ringerfundin).

NCT ID: NCT01935245 Completed - Thrombocytopathy Clinical Trials

Platelet Function in Minimal Extracorporeal Circulation in CABG

ECCTEG
Start date: April 2013
Phase: N/A
Study type: Interventional

Rationale: Cardiac surgery with extracorporeal circulation (ECC) triggers platelets. Minimal extracorporeal circulation system (minimal-ECC) has several advantages compared with conventional ECC amongst less platelet activation. Platelet function can be analysed with thromboelastography (TEG) and multiple electrode aggregometry (MEA). Objective: The use of minimal ECC leads to less platelet dysfunction compared with conventional ECC in coronary artery bypass grafting (CABG) analysed with TEG and MEA Study design: Single center, prospective, randomized, pilot study Study population: Group 1: 20 patients undergoing CABG using minimal ECC. Patients continued the use of acetylsalicylic acid and discontinued the use of clopidogrel minimal 5 days preoperative. Group 2: 20 patients undergoing CABG using conventional ECC. Patients continued the use of acetylsalicylic acid and discontinued the use of clopidogrel minimal 5 days preoperative. Intervention: Group 1: CABG using minimal ECC Group 2: CABG using conventional ECC Main study parameters/endpoints: 1. Results of TEG and MEA, see detailed description 2. Per operative blood loss and total blood loss 24 hours after CABG 3. Total amount of transfused platelet units during CABG and 24 hours after CABG

NCT ID: NCT01344096 Recruiting - Gaucher Disease Clinical Trials

Thrombocytopathy in Gaucher Disease Patients

Start date: October 2010
Phase: N/A
Study type: Observational

In Gaucher disease type I bleeding is a common presenting symptom, that may manifest itself as frequent nose bleeds, easy bruising but can also cause substantial bleeding after surgical or dental procedures and may occur in association with pregnancy or delivery . The bleeding tendency is usually considered to be secondary to thrombocytopenia However 50,000 platelets are enough in healthy people to give a normal bleeding time but are associated with significant bleeding tendencies in Gaucher patients. Bleeding tendency might be attributed by genetic inherited or Gaucher related coagulation factors abnormalities which in some cases stabilize with ERT. However, In other cases the etiology is an abnormality of platelet function. This thrombocytopathy has not been delineated and apart from a few aggregation studies, no systematic analysis has been published that convincingly shows the cause of the disturbed function. While, experience shows that enzyme replacement (ERT, i.e: imiglucerase, Cerezyme®) reduces this bleeding tendency, in part due to the improvement in the thrombocyte count and elevation in coagulation factors, it is less clear what effect ERT has on the thrombocytopathy. This has clinical significance when patients need to be prepared for surgery or delivery or in the event of a major bleed. There is no consensus as to how patients should be prepared or treated. Different centres use different approaches. When the procedure is elective ERT is appropriate but in other situations DDAVP, fresh frozen plasma and platelet infusion are possible treatments. Even activated factor VII has been used when bleeding was not controlled. As in any other coagulation abnormality, treatment should be tailored to the specific cause of the bleeding diathesis. The aim of this study is to define the etiology of platelet dysfunction in Gaucher patients. Hypothesis: The investigators expect to see a difference between platelets activation profile among imiglucerase treated and untreated patients with at least a partial restoration of platelets function due to treatment commencement.

NCT ID: NCT00182156 Withdrawn - Clinical trials for Cardiovascular Diseases

Cohort Study Comparing Short Daily Hemodialysis (HD) With Conventional HD

Start date: October 2004
Phase:
Study type: Observational

This study is examining the effects of short daily hemodialysis on platelet function, fluid volume control, arterial stiffness and patient quality of life, as compared to conventional hemodialysis.